Market
Understand market structure changes, launch dynamics, and access shifts that affect asset and company valuations.
3 signals
STRATEGY
Alembic Pharmaceuticals has submitted ANDA220639 for review with a standard review priority.
STRATEGY
AstraZeneca reported a 13% increase in total revenue for Q1 2026, driven by strong product sales and positive readouts from new molecular entities (NMEs).
STRATEGY
Healthcare providers in South Africa support the Dual Prevention Pill (DPP) for HIV and pregnancy prevention but express concerns about daily dosing and side effects.
Showing 1–3 of 3 records
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.